Pediatric AML and CD123 Flow Cytometry: Phenotype Is Not Prognosis

The clinical question behind CD123 flow cytometry

CD123, the interleukin-3 receptor alpha chain, is attractive in acute myeloid leukaemia (AML) because it can be found on blasts and implicated immature compartments. Three different claims are often mixed up: that a marker is expressed, that its expression correlates with disease biology, and that it predicts outcome independently of known risk factors. These require different evidence. Mohammed and colleagues addressed the outcome question in a retrospective paediatric AML cohort; their published report is Frontiers in Oncology (2026), DOI 10.3389/fonc.2026.1879782.

What the 403-patient cohort measured

Investigators studied 403 children with de novo AML treated at Children's Cancer Hospital Egypt-57357 during 2018-2021, with specified exclusions including acute promyelocytic leukaemia, therapy-related disease and cases without CD123 information. Diagnostic multiparameter flow cytometry defined CD123 positivity as expression on at least 20% of identified AML blasts. By this operational definition, 141 of 403 children (35%) were CD123-positive, and the median expression among positive cases was 46%. The percentage depends on the analytical threshold and the chosen blast denominator; it should not be described as a universal prevalence of CD123-positive AML.

Positive cases had higher leukocyte counts (P = 0.003) and marrow blast fractions (P = 0.02). CD123 positivity also occurred more often in M4/M5 FAB phenotypes (P below 0.001) and in cases with FLT3-ITD (P = 0.001). These observational associations can inform biological hypotheses, but do not prove that CD123 drives these disease characteristics or that targeting it improves survival.

Outcome results were not statistically different

Three-year event-free survival was 45.3% in the CD123-positive group versus 42.2% in the CD123-negative group (P = 0.5). Overall survival at three years was 51.7% versus 49.0% (P = 0.6). Three-year cumulative incidence of relapse was 24.1% versus 23.7% (P = 0.9). The differences were small relative to the uncertainty, and the investigators did not identify a significant prognostic separation by the chosen flow threshold.

Multivariable modelling reached the same central interpretation: CD123 positivity had an overall-survival hazard ratio of 0.87 (95% confidence interval 0.65-1.18; P = 0.39) and an event-free survival hazard ratio of 0.85 (95% confidence interval 0.64-1.13; P = 0.28). Neither confidence interval rules out every clinically relevant effect. A non-significant result is not proof that all CD123-defined subgroups are biologically identical, particularly in a retrospective cohort with treatment and genetic heterogeneity.

What to preserve in the flow report

For clinical flow cytometry, recording only CD123-positive or CD123-negative loses information. Preserve blast identification strategy, aberrancy pattern, staining performance, marker intensity relative to appropriate normal comparators, percentage among defined blasts, event adequacy and the instrument and antibody configuration. Document the distinction between a threshold based on percentage of blasts and a continuous antigen intensity measure. The 20% study cutoff is not a validated threshold for deciding therapy or MRD status.

CD123 should also not be confused with the MRD readout used after treatment in the same clinical programme. The investigators describe a separate multiparametric flow MRD assessment after induction and a 0.1% threshold for risk-stratification decisions; these are different specimen times, denominators and clinical endpoints. Importing the diagnostic CD123 cutoff into a post-treatment MRD workflow would be a category error.

Target expression does not establish therapeutic benefit

Antigen-targeted treatment development must confront disease heterogeneity, antigen density, normal tissue expression and target escape. Demonstrating expression does not by itself prove that a particular patient would respond to CD123-directed agents. This study did not randomise patients to CD123-directed therapies, and does not supply efficacy estimates for those treatments. It also did not prospectively validate a new diagnostic assay for multiple instruments, laboratories or jurisdictions.

Daily Learning Pill: three different endpoints

CD123 can be associated with a molecular subtype without predicting survival after adjustment. Always identify whether a paper addresses phenotypic association, independent prognosis or response to a targeted intervention before using the result in a clinical statement.

Clinical interpretation and next step

For paediatric AML, integrate flow findings with molecular classification, morphology, MRD response and protocol-specific risk groups. Check CFCM clinical flow cytometry resources for panel validation and MRD interpretation. This original Technical Review provides evidence appraisal, not independent peer review, local assay validation or patient-specific medical advice.